| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Division of Rheumatology and Clinical Immunogenetics, Department of Internal Medicine, University of Texas Health Science Center, Houston, TX 77030;
Department of Microbiology, Mount Sinai Medical School, New York, NY 10029;
Second Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan;
Department of Medicine and Clinical Science, Kyoto University, Graduate School of Medicine, Kyoto, Japan;
¶ Department of Rheumatology, Juntenko School of Medicine, Tokyo, Japan;
|| Department of Immunology and Microbiology, Medical University of South Carolina, Charleston, SC 29425; and
# Division of Connective Tissue Diseases, University of Tennessee, Memphis, TN 38163
A duplication in the fibrillin-1 gene has been implicated as the cause of the tight skin 1 (tsk1) phenotype, an animal model of scleroderma or systemic sclerosis (SSc). In addition to the production of abnormal fibrillin-1 protein, the tsk1 mouse also produces autoantibodies to fibrillin-1. Among a population of Choctaw Native Americans with the highest prevalence of SSc yet described, a chromosome 15q haplotype containing the fibrillin-1 gene has been strongly associated with SSc. With a recombinant human fibrillin-1 protein, autoantibodies to fibrillin-1 were detected in the sera of Native American SSc patients that correlated significantly with disease. Abs to fibrillin-1 also were detected in sera from Japanese, Caucasian, and African-American SSc patients. Compared with other ethnic groups, Japanese and Native American SSc patients had significantly higher frequencies of anti-fibrillin-1 Abs. Sera from patients with diffuse SSc, calcinosis, Raynaud’s, esophageal dysmotility, sclerodactyly, and telangiectasias syndrome and mixed connective tissue disease also had significantly higher frequencies of anti-fibrillin-1 Abs than sera from controls or patients with other non-SSc connective tissue diseases (lupus, rheumatoid arthritis, and Sjögren’s syndrome). Ab specificity for fibrillin-1 was demonstrated by the lack of binding to a panel of other purified autoantigens. The results presented demonstrate for the first time the presence of high levels of anti-fibrillin-1 Abs in a significant portion of patients with SSc.
This article has been cited by other articles:
|
|
 |
|
  K Komura, M Fujimoto, K Yanaba, T Matsushita, Y Matsushita, M Horikawa, F Ogawa, K Shimizu, M Hasegawa, K Takehara, et al. Blockade of CD40/CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse Ann Rheum Dis, June 1, 2008; 67(6): 867 - 872. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hasegawa, Y. Hamaguchi, K. Yanaba, J.-D. Bouaziz, J. Uchida, M. Fujimoto, T. Matsushita, Y. Matsushita, M. Horikawa, K. Komura, et al. B-Lymphocyte Depletion Reduces Skin Fibrosis and Autoimmunity in the Tight-Skin Mouse Model for Systemic Sclerosis Am. J. Pathol., September 1, 2006; 169(3): 954 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zhou, F. K. Tan, D. M. Milewicz, X. Guo, C. A. Bona, and F. C. Arnett Autoantibodies to Fibrillin-1 Activate Normal Human Fibroblasts in Culture through the TGF-{beta} Pathway to Recapitulate the "Scleroderma Phenotype" J. Immunol., October 1, 2005; 175(7): 4555 - 4560. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Takehara and S. Sato Localized scleroderma is an autoimmune disorder Rheumatology, March 1, 2005; 44(3): 274 - 279. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
